

AREA PRESCRIBING COMMITTEE – ACTION LIST 18 th FEBRUARY 2016							
Action Reference	Minute Reference	ACTION	OWNER	FURTHER COMMENTS	TARGET DATE	STATUS (R/A/Clear)	
14/050	134/14	Add second line use of anti-TNFs for psoriatic arthritis in line with the decisions of the IFR panel.	LA	To be added to Blueteq	14.04.2016	RED ONGOING	
		AC	TIONS FOR 2	2015			
15/42	26/15	Lothian Annual Declaration of Interest Form To be developed and completed annually by committee members.	LA		14.04.2016	ONGOING	
15/34	72/15	NG 14-Melanoma – assessment & management	LA BG PB	Vitamin D guidelines are under review, working group to be set up including MO team BG (NCUHT) and PB (UHMBT) to review and update all current guidelines, to be brought to June 2016 meeting after approval at the relevant Medicine Management Trust groups	16.06.2016	ONGOING	
15/37	108/15	Guidelines for the use of Feminising Hormone therapy in gender dysphoria Suggested changes to include local details to be incorporated into document and brought back to next meeting for approval	LA	Currently being localised by MO Team	14.04.2016	ONGOING	
15/38	109/15	Guidelines for the use of Masculinising Hormone therapy in gender dysphoria Suggested changes to include local details to be incorporated into document and brought back to next meeting for approval	LA	Currently being localised by MO Team	14.04.2016	ONGOING	
15/39	111/15	Sulfasalazine SCG Review for gastro indications.	РВ	For Gastro indications the SCG will be updated with monitoring requirements	14.04.2016	ONGOING	



15/43	126/15	Azathioprine & Mercaptopurine SCG		LA to review the SCG taking comments from		ssioning Group
		To be reviewed in light of gastroenterologist comments.	LA	Mr Dennis Burke and Dr Shadad (both NCUHT) into account	14.04.2016	ONGOING
15/44	127/15	LJF Amendments –		Information should be taken to the Cumbria		
		November 2015 4.10 (f) Diazepam Prescribing	LA	LIN meeting on the 24.3.16 for a decision on a course of action.	14.04.2016	ONGOING
15/46	128/15	TA358 Tolvaptan	LA	Commissioner status to be checked.	14.04.2016	ONGOING
15/48	131/15	Algorithm for blood glucose lowering therapy in		Will be reviewed and adapted with local		
		adults with type 2 diabetes		formulary drug choices for Cumbria	14 04 2016	ONCOINC
		Review algorithm and adopt with local formulary drug choices.	LA		14.04.2016	ONGOING
15/53	143/15b	Prescribing review: LHRH Agonists	BG	Comments on recommendation 2 & 3 to be	14.04.2016	ONGOING
			PB	brought back to next meeting.		
15/54	144/15	Prescribing review: Antipsychotic drugs	LA	Rec 2: Written communication will be sought from CPFT Medical Director to support GP's	18.02.2016	ONGOING
				to implement this recommendation.		
01/16	01/16	APC Terms of Reference	PU	Updated version to be circulated for ratification at the April meeting.	14.04.2016	
02/16	02/16	Review of COPD guidance	BG	Amended documents to be brought to the next meeting.	14.04.2016	
03/16	03/16	Lothian Joint Formulary review	LA	Working group members: PB,LA, AL, HH, Chris	14.04.2016	
		Working group to be set up to discuss the options		Brewer – to meet before the April APC		
		for formulary in light of discrepancies between		meeting.		
		Lothian and NICE.				



						ssioning droup
04/16	08/16	NICE MO Baseline Assessment	AL	AL to share transfer of care audit at the next meeting of the LPN	14.04.2016	
05/16	11/16	NOAC Guidance Comment was made on the 1 st Care Cumbria "AF - which NOAC to use" document around its convenience however evidence and references to be provided and drug choices should be in line with NICE guidance.	АМ	AM to ask the author to provide this for April meeting.	14.04.2016	
06/16	12/16	GP concerns over new SCG format	AP PB	AP and PB to follow up with UHMBT	14.04.2016	
07/16	14/16	STOPP START Toolkit	ALL	Comments back to PU.	14.04.2016	
08/16	15/16	To be brought back to the next meeting with clarification of "Significant deterioration in renal function" and Immunisation required?	PB	Any other comments to PB	14.04.2016	
09/16	18/16	Memantine in combination with AChE RAG status review	НН	Dr Darren Reynolds to be asked to attend the April meeting to appeal the current RED status.	14.04.2016	
10/16	19/16	Insulin Passport	НН	HH to ask Cumbria Diabetes what they recommend.	14.04.2016	
11/16	20/16	Mycophenolate SCG – "Off licence use"	РВ	Final version to be brought to next meeting	14.04.2016	
12/16	21/16	DRUG SAFETY UPDATE – Dec 15	LA	Points 2 & 3 add to Prescription Pad	14.04.2016	
13/16	22/16	DRUG SAFETY UPDATE – Jan 16	LA	Points 1 & 2 add to Prescription Pad	14.04.2016	

